Web resources

 Tumours list


   General information
   Urologic tumour list

   General information
   Rare melanoma list

   General information
   Skin tumor list


(GLS - italian project)
   Info generali
   Scheda dati

   General information
   Member area


partially supported by


24/09/2003 - GISTs: The revolution continues

Gastrointestinal stromal tumors (GISTs) are differentiated from other types of gastrointestinal mesenchymal tumors by the expression of c-kit receptor tyrosine kinase (KIT). More than 80% of GISTs have somatic mutations of the KIT gene and are considered to be caused by the mutations, a finding that allows the KIT inhibitor Imatinib mesylate (formerly known as STI-571) to be used successfully as a molecular target drug for GISTs. A few GISTs, however, do not show the gain-of-function mutations of KIT and, hence, are imatinib unresponsive. Japanese researchers found two types of gain-of-function mutations of PDGFR in 5 of 8 GISTs without KIT mutations but not in 10 GISTs with KIT mutations. The gain-of-function mutations of PDGFR gene might therefore play an important role on development of GISTs without KIT mutations. Read the editorial by William M. Grady as appeared on Gastroenterology 125(3):967-978, September 2003.

News Archive

3/8/2001 WHY?
17/11/2001 W.H.O. Collaborating Centre for Cancer Control of Uncommon Tumours
10/12/2001 On November 30th, in the hall of the S. Pio X Private Hospital of Milan, Italy, the
18/12/2001 Post-meeting survey
3/12/2002 QUIZ
5/5/2002 Dear Colleagues,Notebook Veri Kurtarma
29/01/2003 New publication on rare cancers !
28/07/2003 Thyroid Cancer Treatment Receives Orphan Drug Status
02/08/2003 Breast cancer in men Kiralık Ofis Ankara
28/10/2003 Lessons learned from the management of a rare genetic cancer.
17/11/2003 Successful photodynamic therapy for nonresectable cholangiocarcinoma.
07/01/2004 Gene associated with higher risk of melanoma in men
08/03/2004 Susceptibility to Common Adult Cancers in Retinoblastoma Survivors
29/03/2004 FDA Approves First Drug for mesothelioma
25/08/2004 Gene therapy cures malignant melanoma in mice
20/10/2004 FDA grants orphan drug status to two new anticancer drugs.
15/11/2004 New experimental drug for myeloproliferative disorder
20/01/2005 New leukemia treatment granted FDA orphan drug status.
28/02/2005 U.S. F.D.A. grants new orphan drug designation for a targeted therapeutic for head and neck cancer.
02/05/2005 Possible targets for a multiple myeloma vaccine
17/10/2005 Orphan drug troxacitabine approved for AML in EU
03/11/2005 FDA designes interleukin 21 as an orphan drug
01/12/2005 Zactima has received FDA orphan drug designation
25/01/2006 CETT Program for Rare Genetic Diseases
23/02/2006 New research studies of multiple myeloma